Glenmark Pharmaceuticals Limited announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single Dose Vial in the United States market through its subsidiary, Glenmark Pharmaceuticals Inc., USA. According to reports from Business Standard, the product is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. As per IQVIA® sales data, the ProvayBlue® market achieved annual sales of approximately $19.0 million for the 12-month period ending April 2026, indicating significant market opportunity for Glenmark's entry.
Marc Kikuchi, President & Business Head, North America at Glenmark commented on the launch, stating that the introduction reflects the company's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. As reported by Business Standard, Kikuchi emphasized that this launch further strengthens Glenmark's institutional portfolio and reinforces their focus on delivering reliable treatment options across the U.S. market, with the product's bioequivalence ensuring it will meet the same high standards of efficacy and safety as the reference listed drug.
The launch is expected to provide significant benefits to healthcare providers and patients by enhancing competition in the Methylene Blue Injection market. According to company reports, Glenmark's entry is positioned to potentially lower prices and benefit the broader healthcare system as the market continues to grow. The product's bioequivalence ensures it will meet the same high standards of efficacy and safety as the reference listed drug, while the company's strategic expansion reinforces their commitment to providing reliable treatment options across the U.S. market.
Glenmark Pharmaceuticals reported strong financial results for Q4 FY26, with consolidated net profit zooming 6,381.9% to ₹301.41 crore on a 16.8% increase in revenue from operations to ₹3,760.28 crore compared to Q4 FY25. However, the company's stock performance showed mixed results, with shares falling 1.31% to ₹2,128.50 on the BSE following the announcement. The company is engaged in the business of development, manufacturing, and marketing of pharmaceutical products to regulated and semi-regulated markets.
